Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

260 trials with published results (23%)

Research Maturity

777 completed trials (68% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.5%

86 terminated out of 1146 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

28%

317 trials in Phase 3/4

Results Transparency

33%

260 of 777 completed with results

Key Signals

260 with results90% success86 terminated

Data Visualizations

Phase Distribution

901Total
Not Applicable (440)
Early P 1 (5)
P 1 (55)
P 2 (84)
P 3 (150)
P 4 (167)

Trial Status

Completed777
Unknown119
Terminated86
Recruiting84
Withdrawn30
Active Not Recruiting22

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 777 completed trials

Clinical Trials (1146)

Showing 20 of 20 trials
NCT04815239Not ApplicableActive Not RecruitingPrimary

Early Intervention for Youth at High Risk for Bipolar Disorder

NCT07105111Phase 4Recruiting

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT04675593Not ApplicableCompletedPrimary

Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders

NCT07140913Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT03898297Completed

Imaging mGluR5 and Synaptic Density in Psychiatric Disorders

NCT00024635Recruiting

Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers

NCT00001174Active Not RecruitingPrimary

Evaluation of the Genetics of Bipolar Disorder

NCT07043803Not ApplicableCompleted

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NCT04276883Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

NCT07286175Phase 2RecruitingPrimary

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

NCT07217860Phase 3Enrolling By Invitation

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

NCT04622150Not ApplicableCompletedPrimary

Effectiveness RCT of Customized Adherence Enhancement

NCT07172516Phase 3RecruitingPrimary

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT05172271Not ApplicableActive Not Recruiting

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

NCT06782763Not ApplicableCompletedPrimary

Efficacy and Safety of Task-activated rTMS in Improving Cognitive Function in Patients With Bipolar Disorder

NCT05929183Not ApplicableCompletedPrimary

Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent

NCT07592884Not ApplicableCompleted

Rochester Forensic Assertive Community Treatment Model in Minnesota

NCT05625555Phase 3Active Not Recruiting

Predictors of Intravenous Ketamine Response in TRD

NCT05699525Not ApplicableRecruiting

Personalized Mobile Cognitive Behavioral Therapy Application

NCT02878408Not ApplicableRecruitingPrimary

Immuno-Genetic, Inflammation, Retro-Virus, Environment

Scroll to load more

Research Network

Activity Timeline